Quotient Sciences
@quotientsciences.bsky.social
Offering formulation development, clinical pharmacology, clinical & commercial manufacturing services to the #pharmaceutical & #biotech industry as an integrated #CRO / #CDMO. Molecule to cure, fast. https://bit.ly/40RrMoh
With experience spanning 35 years and more than 1,300 Phase I studies delivered, learn how #QuotientSciences can help accelerate to first-in-human and proof of concept milestones with confidence: bit.ly/3KX2X4r
Early Clinical Development
Partner with us to design and deliver your early clinical programs.
bit.ly
October 21, 2025 at 1:57 PM
With experience spanning 35 years and more than 1,300 Phase I studies delivered, learn how #QuotientSciences can help accelerate to first-in-human and proof of concept milestones with confidence: bit.ly/3KX2X4r
Dr. Andy Lewis, Chief Scientific Officer, recently contributed to PharmaSource's article, "How to Build Resilient Pharma-CDMO Partnerships in 2025". Hear Dr. Lewis' perspective on building lasting partnerships that can withstand the industry challenges of today: bit.ly/4pZM5dv
October 9, 2025 at 3:45 PM
Dr. Andy Lewis, Chief Scientific Officer, recently contributed to PharmaSource's article, "How to Build Resilient Pharma-CDMO Partnerships in 2025". Hear Dr. Lewis' perspective on building lasting partnerships that can withstand the industry challenges of today: bit.ly/4pZM5dv
We’re raising the UN Sustainable Development Goals (SDGs) flag today in recognition of our focus on turning ambition into action across our sites and teams #togetherfortheSDGs with the UN Global Compact Network UK.
Learn more about our ongoing commitment to #ESG initiatives: bit.ly/42OPC3F
Learn more about our ongoing commitment to #ESG initiatives: bit.ly/42OPC3F
September 25, 2025 at 9:39 PM
We’re raising the UN Sustainable Development Goals (SDGs) flag today in recognition of our focus on turning ambition into action across our sites and teams #togetherfortheSDGs with the UN Global Compact Network UK.
Learn more about our ongoing commitment to #ESG initiatives: bit.ly/42OPC3F
Learn more about our ongoing commitment to #ESG initiatives: bit.ly/42OPC3F
Dr. Dolly Jacob, Director of Integrated Development Services, discusses capabilities of our Miami, FL on-site compounding pharmacy to accelerate first-in-human to proof-of-concept #clinicaltrials: bit.ly/4fr4wD2
September 22, 2025 at 4:09 PM
Dr. Dolly Jacob, Director of Integrated Development Services, discusses capabilities of our Miami, FL on-site compounding pharmacy to accelerate first-in-human to proof-of-concept #clinicaltrials: bit.ly/4fr4wD2
Robert Cornog, Senior Director of Product Development & Brad Rowe, Senior Director of Integrated Development contributed to Contract Pharma's feature on #HPAPI outsourcing, speaking on the demand, #regulatory shifts, and analytical challenges shaping the contract manufacturing market. bit.ly/4njmfPF
September 9, 2025 at 10:59 PM
Robert Cornog, Senior Director of Product Development & Brad Rowe, Senior Director of Integrated Development contributed to Contract Pharma's feature on #HPAPI outsourcing, speaking on the demand, #regulatory shifts, and analytical challenges shaping the contract manufacturing market. bit.ly/4njmfPF
Last week, we celebrated 35 years of #QuotientSciences. Our CEO, Thierry Van Nieuwenhove, reflects on our mission and success in combining science, agility, and culture to make a real difference for our customers, partners, and the lives of people around the world. Learn more: bit.ly/3SeKCQV
September 8, 2025 at 4:40 PM
Last week, we celebrated 35 years of #QuotientSciences. Our CEO, Thierry Van Nieuwenhove, reflects on our mission and success in combining science, agility, and culture to make a real difference for our customers, partners, and the lives of people around the world. Learn more: bit.ly/3SeKCQV
NEWS: Quotient Sciences and CPI's joint venture marks a major step forward in RNA drug development.
Using our Translational Pharmaceutics® platform and CPI’s RNA manufacturing expertise, we aim to streamline the development of promising treatments for patients. Read announcement: bit.ly/4lMKRin
Using our Translational Pharmaceutics® platform and CPI’s RNA manufacturing expertise, we aim to streamline the development of promising treatments for patients. Read announcement: bit.ly/4lMKRin
September 3, 2025 at 2:17 PM
NEWS: Quotient Sciences and CPI's joint venture marks a major step forward in RNA drug development.
Using our Translational Pharmaceutics® platform and CPI’s RNA manufacturing expertise, we aim to streamline the development of promising treatments for patients. Read announcement: bit.ly/4lMKRin
Using our Translational Pharmaceutics® platform and CPI’s RNA manufacturing expertise, we aim to streamline the development of promising treatments for patients. Read announcement: bit.ly/4lMKRin
Our #formulationdevelopment services support customers from preclinical to late-stage clinical evaluation. Learn more about how we can help address formulation issues quickly and optimize your molecule's performance: bit.ly/4lYTVBB
August 22, 2025 at 6:20 PM
Our #formulationdevelopment services support customers from preclinical to late-stage clinical evaluation. Learn more about how we can help address formulation issues quickly and optimize your molecule's performance: bit.ly/4lYTVBB
Latest #blog: Nazim Kanji, Executive Director of Pediatric Services, summarizes findings from a poster focusing on a taste assessment study of tenapanor pediatric solution formulations from EuPFI 2023. Read here: bit.ly/411T76S
August 13, 2025 at 8:38 PM
Latest #blog: Nazim Kanji, Executive Director of Pediatric Services, summarizes findings from a poster focusing on a taste assessment study of tenapanor pediatric solution formulations from EuPFI 2023. Read here: bit.ly/411T76S
Careful selection of appropriate delivery technologies is key to the design of successful modified-release formulations. Download our info sheet to learn how we can help reduce development risks and maximizing the chance of success for your treatment: bit.ly/4f6kwKI
Modified-Release Formulation Strategies
With over 30 years of formulation expertise and over 100 MR programs developed, the team at Quotient Sciences possess the experience, capabilities, and technologies needed to create a successful MR fo...
bit.ly
August 11, 2025 at 3:02 PM
Careful selection of appropriate delivery technologies is key to the design of successful modified-release formulations. Download our info sheet to learn how we can help reduce development risks and maximizing the chance of success for your treatment: bit.ly/4f6kwKI
In our latest blog, Dr. Dolly Jacob, Director of Integrated Development Services, speaks about the capabilities of our Miami, FL on-site compounding pharmacy and ideal uses for pharmacy compounding to accelerate FIH to POC trials. Learn more: bit.ly/4fr4wD2
August 8, 2025 at 7:00 PM
In our latest blog, Dr. Dolly Jacob, Director of Integrated Development Services, speaks about the capabilities of our Miami, FL on-site compounding pharmacy and ideal uses for pharmacy compounding to accelerate FIH to POC trials. Learn more: bit.ly/4fr4wD2
#ICYMI: Robert Cornog, Senior Director of Product Development, and Dr. Kevin Schaab, Senior Drug Development Consultant, share their insight about their visit to BIO International Convention 2025: bit.ly/44knuWS
July 30, 2025 at 2:14 PM
#ICYMI: Robert Cornog, Senior Director of Product Development, and Dr. Kevin Schaab, Senior Drug Development Consultant, share their insight about their visit to BIO International Convention 2025: bit.ly/44knuWS
Dr. Andy Lewis, Chief Scientific Officer, examines how CMC and clinical strategies for #peptide drugs can be improved, answering questions on the challenges and potential solutions associated with development of injectable and oral peptide drugs in our latest whitepaper: bit.ly/4kPtcGP
July 25, 2025 at 1:05 PM
Dr. Andy Lewis, Chief Scientific Officer, examines how CMC and clinical strategies for #peptide drugs can be improved, answering questions on the challenges and potential solutions associated with development of injectable and oral peptide drugs in our latest whitepaper: bit.ly/4kPtcGP
In this article from Pharmaceutical Outsourcing, John McDermott, VP of Scientific Consulting, talks about the evolving landscape of oral solid dosage manufacturing and highlights the importance of small, agile #CDMOs to meet the diverse demands of modern #drugdevelopment. bit.ly/4lmAjHd
July 22, 2025 at 12:49 PM
In this article from Pharmaceutical Outsourcing, John McDermott, VP of Scientific Consulting, talks about the evolving landscape of oral solid dosage manufacturing and highlights the importance of small, agile #CDMOs to meet the diverse demands of modern #drugdevelopment. bit.ly/4lmAjHd
Latest news: #QuotientSciences has formed a scientific advisory board of established leaders from industry and academia. The board will contribute to driving innovation and technology aligned with company strategic priorities. bit.ly/3TOukPs
Quotient Sciences Announces Formation of Scientific Advisory Board
Advisory board will contribute to driving innovation and technology aligned with company strategic priorities. Inaugural board participants include established pharma & biotech executives, academics.
bit.ly
July 16, 2025 at 12:07 PM
Latest news: #QuotientSciences has formed a scientific advisory board of established leaders from industry and academia. The board will contribute to driving innovation and technology aligned with company strategic priorities. bit.ly/3TOukPs
Latest #whitepaper: Learn more about how we help customers navigate the #drugdevelopment pathway, meeting the #regulatory requirements of products granted expedited development and review, as well as generating data needed to support drug approval. Download today: bit.ly/46g7KqD
July 16, 2025 at 12:05 PM
Latest #whitepaper: Learn more about how we help customers navigate the #drugdevelopment pathway, meeting the #regulatory requirements of products granted expedited development and review, as well as generating data needed to support drug approval. Download today: bit.ly/46g7KqD
In our latest blog, Brad Rowe, Senior Director of Integrated Development, and Robert Cornog, Senior Director of Product Development, share insight on how our team can help clients successfully leverage accelerated approval pathways.
Read more: bit.ly/4lrooIc
Read more: bit.ly/4lrooIc
July 10, 2025 at 6:48 PM
In our latest blog, Brad Rowe, Senior Director of Integrated Development, and Robert Cornog, Senior Director of Product Development, share insight on how our team can help clients successfully leverage accelerated approval pathways.
Read more: bit.ly/4lrooIc
Read more: bit.ly/4lrooIc
Latest announcement: Quotient Sciences announces the reintroduction of Arcinova - A Quotient Sciences Company.
Through a focus on quality, science, and innovation, Arcinova provides innovative research, development, and manufacturing services to advance drug development. Reade more: bit.ly/3HWORif
Through a focus on quality, science, and innovation, Arcinova provides innovative research, development, and manufacturing services to advance drug development. Reade more: bit.ly/3HWORif
June 24, 2025 at 9:45 PM
Latest announcement: Quotient Sciences announces the reintroduction of Arcinova - A Quotient Sciences Company.
Through a focus on quality, science, and innovation, Arcinova provides innovative research, development, and manufacturing services to advance drug development. Reade more: bit.ly/3HWORif
Through a focus on quality, science, and innovation, Arcinova provides innovative research, development, and manufacturing services to advance drug development. Reade more: bit.ly/3HWORif
#ICYMI: In this video interview with BioPharm International, Dr. Helen Baker, Director of Formulation Design, discusses the benefits of having #clinical, late-stage, and #regulatory processes under one provider. Learn more: bit.ly/3XKlchg
June 6, 2025 at 9:18 PM
#ICYMI: In this video interview with BioPharm International, Dr. Helen Baker, Director of Formulation Design, discusses the benefits of having #clinical, late-stage, and #regulatory processes under one provider. Learn more: bit.ly/3XKlchg
Our Philadelphia teams are committed to delivering high-quality services for #drugproduct formulation & manufacturing. Learn about the important role these sites have in facilitating #TranslationalPharmaceutics® programs in collaboration with our Miami clinical pharmacology facility: bit.ly/422ysQR
June 2, 2025 at 1:52 PM
Our Philadelphia teams are committed to delivering high-quality services for #drugproduct formulation & manufacturing. Learn about the important role these sites have in facilitating #TranslationalPharmaceutics® programs in collaboration with our Miami clinical pharmacology facility: bit.ly/422ysQR
#ICYMI: Dr. Helen Baker, Director of Formulation Design, and Dr. Richard Castledine, Head of Drug Substance Operations, contributed to Pharmaceutical Technology's issue, 'Poor API Quality Threatens a Healthy Supply'. Learn more about the importance of high quality API: bit.ly/3FczGjU
May 28, 2025 at 12:02 PM
#ICYMI: Dr. Helen Baker, Director of Formulation Design, and Dr. Richard Castledine, Head of Drug Substance Operations, contributed to Pharmaceutical Technology's issue, 'Poor API Quality Threatens a Healthy Supply'. Learn more about the importance of high quality API: bit.ly/3FczGjU
#TranslationalPharmaceutics® has been a core part of #QuotientSciences’ approach for nearly two decades. Download our recently updated info sheet to learn more about how it works to accelerate drug programs: bit.ly/4iH9JqI
Translational Pharmaceutics® Integrated Drug Development Info Sheet
Quotient Sciences Translational Pharmaceutics® platform for drug development helps you achieve your goals by enabling a significantly faster transition through drug development by integrating on-deman...
bit.ly
May 28, 2025 at 11:59 AM
#TranslationalPharmaceutics® has been a core part of #QuotientSciences’ approach for nearly two decades. Download our recently updated info sheet to learn more about how it works to accelerate drug programs: bit.ly/4iH9JqI
Dr. Helen Baker, Director of Formulation Design, and Dr. Richard Castledine, Head of Drug Substance Operations, contributed to Pharmaceutical Technology's latest issue, 'Poor API Quality Threatens a Healthy Supply'. Learn more about the importance of high quality API here: bit.ly/3FczGjU
May 16, 2025 at 9:20 PM
Dr. Helen Baker, Director of Formulation Design, and Dr. Richard Castledine, Head of Drug Substance Operations, contributed to Pharmaceutical Technology's latest issue, 'Poor API Quality Threatens a Healthy Supply'. Learn more about the importance of high quality API here: bit.ly/3FczGjU
Will you be in Philadelphia for #CPHIAmericas next week? Meet with our team at booth #1220 to learn more about our expanded service offerings and how #QuotientSciences can help you overcome your program challenges. Request a meeting today: bit.ly/3G1GIbr
May 14, 2025 at 9:52 PM
Will you be in Philadelphia for #CPHIAmericas next week? Meet with our team at booth #1220 to learn more about our expanded service offerings and how #QuotientSciences can help you overcome your program challenges. Request a meeting today: bit.ly/3G1GIbr
We recently celebrated #NursesWeek and #ClinicalOperations Appreciation Day at our Miami and Nottingham sites! We are proud to recognize the hard work and dedication of our teams each day! #lifeatquotient
May 14, 2025 at 2:22 AM
We recently celebrated #NursesWeek and #ClinicalOperations Appreciation Day at our Miami and Nottingham sites! We are proud to recognize the hard work and dedication of our teams each day! #lifeatquotient